ACTG 5097s found that people who identified as black or Hispanic maintained higher blood levels of efavirenz than their white non-Hispanic counterparts. As might be expected, people with higher blood levels of the drug were more likely to stop taking it due to side effects. The study also found that while people with higher efavirenz blood levels did not develop CNS side effects more rapidly than those with lower blood levels, they were more likely to stop taking efavirenz because of them. This suggests that while CNS effects aren't developing more rapidly among people with higher blood levels of drug, when they do occur they are more severe.
Upon closer examination, researchers found a genetic variation that explained the difference in how people's bodies processed efavirenz better than racial identification. This genetic variation, which affects how the liver functions, was found in 20% of black participants and only 3% of white participants. No data were presented regarding the percentage of Hispanic study participants who carry the gene. The genetic tests used in this study are unlikely to be available anytime soon. In the absence of access to these tests, Blacks and Hispanics who are taking efavirenz should be aware of a potential increased risk of side effects and continue careful monitoring.
Further confirmation of the genetic variation, its impact on liver function and the people most likely to carry it is needed to determine its impact on peoples' response to anti-HIV treatment.
Back to the Project Inform Perspective July 2004 contents page.